Nonetheless, the reliable identification of cancer-driving POLE mutations in a cost-effective manner remains a significant challenge, although several POLE assays not based on NGS have been described that should be capable of reliably identifying POLE mutations [12]. The gene discussed is POLE; the disease is cancer.